方盛制药(603998) - 投资者关系活动记录表（2024-034)

Financial Performance - In the first half of 2024, the company achieved operating revenue of 910.25 million yuan, a year-on-year increase of 6.44% compared to the first half of 2023 [1] - The net profit attributable to shareholders was 136.84 million yuan, reflecting a year-on-year growth of 28.23% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 110.71 million yuan, up 26.54% year-on-year [1] Research and Development - The company has initiated 13 innovative traditional Chinese medicine (TCM) projects in preclinical research, covering various medical fields including gynecology, orthopedics, respiratory, pediatrics, and oncology [2] - The innovative TCM product "Yiqi Xiaoliu Granules" has received approval for clinical trials from the National Medical Products Administration [2] Product Sales - Revenue from respiratory system medications reached 146.32 million yuan in the first half of 2024, a year-on-year increase of 12.09%, primarily driven by strong sales of "Qiangli Pipa Gao" [2] - "Qiangli Pipa Gao" generated sales of 135 million yuan, with a growth of over 26% year-on-year, while "Qiangli Pipa Lu" saw a decline of approximately 52% with sales of 11.27 million yuan [2] - The innovative TCM products "Xiaoer Jingxing Zhi Ke Granules" and "Xuanqi Jianguo Pian" have shown promising market expansion, with the former covering over 1,500 public medical institutions by June 30, 2024, and achieving sales of approximately 45 million yuan, a growth of over 150% [2][3] Future Outlook - The company anticipates a revenue growth of no less than 5% year-on-year for 2024, considering the impact of national centralized procurement on product pricing [4] - The net profit attributable to shareholders is expected to grow between 20% and 35% year-on-year [4] - The management emphasizes the importance of market conditions, operational environment, and industry policies in achieving these targets, highlighting the inherent uncertainties [4]